INNOVATIVE RESEARCH IN CANCER NANOTECHNOLOGY (IRCN) (U01)
APPLICATION SUBMISSION DEADLINE: October 29, 2014
FUNDING OPPORTUNITY ANNOUNCEMENT #: PAR-14-285
AWARD PERIOD: Earliest Start Date: September 2015
AWARD BUDGET: Limited to $450,000 in direct costs per year for up to 5 years of support.
The purpose of this funding opportunity announcement (FOA) on Innovative Research in Cancer Nanotechnology (IRCN) is to expand the fundamental understanding of the processes pertinent to the use of nanotechnology in cancer. Projects supported by the IRCN initiative should be multi-disciplinary and generate new fundamental knowledge associated with the development of nanotechnology-based solutions to major problems in cancer-biology and/or oncology. The outcomes of IRCN-supported projects should inspire and aid the ultimate development of innovative, clinically relevant nanotechnology solutions for cancer (although prospective clinical translation of the IRCN findings remains beyond the scope of this FOA).
The IRCN initiative is an integral part of the NCI Alliance for Nanotechnology in Cancer program. In addition to IRCN U01 projects supported by this FOA, the Alliance will consist of the Centers of Cancer Nanotechnology Excellence (CCNEs, supported by U54 RFA-CA-14-013) and T32 training programs (supported through PA-14-015).
CENTERS OF CANCER NANOTECHNOLOGY EXCELLENCE (CCNEs) (U54)
APPLICATION SUBMISSION DEADLINE: November 3, 2014
FUNDING OPPORTUNITY ANNOUNCEMENT #: RFA-CA-14-013
AWARD PERIOD: Earliest Start Date: September 2015
AWARD BUDGET: Application budgets for each Center may not exceed $2.6 million in total costs per year and need to reflect the actual needs of the proposed project . Applicants may request up to 5 years of support.
This Funding Opportunity Announcement (FOA) solicits applications for Centers of Cancer Nanotechnology Excellence (CCNE) that will be a main part of the NCI Alliance for Nanotechnology in Cancer (The Alliance) program (http://nano.cancer.gov). Whereas CCNEs will form the core of the Alliance, they will be accompanied by smaller Innovative Research in Cancer Nanotechnology (IRCN) awards and T32 training programs. This FOA is open to all qualified applicants regardless of whether or not they participated in the previous issuance of the program. CCNEs are designed to link physical scientists, engineers, and technologists working at the nanoscale with cancer biologists and oncologists specializing in the diagnosis, prevention, and/or treatment of cancer to enable development and translation of new cancer care applications based on nanotechnology. CCNE awards will support the development of techniques and tools that are applicable to: early disease diagnosis using in vitro assays and devices or in vivo imaging techniques; multifunctional therapeutic solutions, including nanoparticle-driven immunotherapies; and techniques for cancer prevention and control. Multi-disciplinary research teams submitting applications should collectively have the breadth of expertise that would allow them to: (a) identify an overarching problem in cancer biology and/or oncology that can be addressed with a multi-project approach leveraging nanotechnology and (b) demonstrate the translational potential of the technologies proposed in the above mentioned projects. The overall goal is a rapid advance of novel cancer care applications based on nanotechnology. NCI will hold a pre-application informational webinar for this FOA. Date, time, and other details will be posted at http://nano.cancer.gov/phase3info.
THE NATIONAL CANCER INSTITUTE OUTSTANDING INVESTIGATOR AWARD (R35)
FUNDING OPPORTUNITY ANNOUNCEMENT #: PAR-14-267
LETTER OF INTENT DUE DATE: September 20, 2014
APPLICATION SUBMISSION DEADLINE: October 20, 2014
AWARD BUDGET: Application budgets (direct costs exclusive of third party facilities and administrative costs) may not exceed $600,000 per year and must reflect the actual needs of the proposed project.
AWARD PROJECT PERIOD: The total project may not exceed 7 years.
Additional Eligibility Requirements:
· Applications must be submitted by Institutions who have nominated a Program Director/Principal Investigator (PD/PI) with outstanding cancer research productivity for at least the past 5 years.
· The Institution-nominated PD/PI must have been a PD/PI on an NCI grant for the last 5 consecutive years.
· Due to the nature of this award, the PD/PI will be expected to commit a major portion (at least 50%) of their research activities to the OIA. Effort expended toward teaching, administrative, or clinical duties should not be included in this calculation. PDs/PIs with effort on other NIH grants will be expected to provide, as part of the Just-in-Time information, a detailed explanation describing how effort on his/her other NIH grants will be adjusted, if necessary, to permit 50% effort on the OIA.
· PD/PIs will need to renegotiate their time and effort on other NIH grants in order to accommodate the OIA level of effort.
In addition, grantee Institutions are expected to: 1) provide clear and continuing commitment to the PD/PI, for example including at least 20% salary support for the duration of the award; 2) agree to relinquish the PD/PI's existing individual NCI awards to allow them to be consolidated into the OIA.
NIH/NCI - EARLY PHASE CLINICAL TRIALS IN IMAGING AND IMAGE-GUIDED INTERVENTIONS (R01)
FUNDING OPPORTUNITY ANNOUNCEMENT #: PAR-14-166
APPLICATION DUE DATES: June 30, 2014 OR October 10, 2014
AWARD BUDGET: Application budget should reflect the actual needs of the proposed project and is limited to $500,000 in direct costs for the total project period. No more than $250,000 in direct costs may be requested in any single year.
AWARD PROJECT PERIOD: The total project period may not exceed 3 years.
DESCRIPTION: This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. This FOA supports novel uses of known/standard clinical imaging agents and methods as well as the evaluation of new agents, systems, or methods. The imaging and image-guided intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Centers and/or the NCI's National Clinical Trials Network.
DOD - BREAST CANCER ERA OF HOPE SCHOLAR AWARD
FUNDING OPPORTUNITY #: W81XWH-14-BCRP-EOHS
PRE-APPLICATION DEADLINE: August 1, 2014
APPLICATION SUBMISSION DEADLINE: August 15, 2014
AWARD BUDGET: The maximum allowable direct costs for the entire period of performance are $2.5M plus indirect costs.
AWARD PROJECT PERIOD: The maximum period of performance is 5 years.
DESCRIPTION: The Era of Hope Scholar Award supports individuals who are early in their careers and have demonstrated significant potential for innovation in breast cancer research. These individuals should be exceptionally talented scientists who have shown that they are the “best and brightest” in their field(s) through extraordinary creativity, vision, and productivity. They should have demonstrated experience in forming effective partnerships and collaborations and should exhibit strong potential for leadership in the breast cancer research community. Since the intent of the Era of Hope Scholar Award is to recognize creative and innovative individuals rather than projects, the central feature of the award is the innovative contribution that the PI can make toward ending breast cancer.